Terms of the deal have not been disclosed.

Based in Cambridge, Oval Medical is engaged in the development of next generation autoinjectors for the self-injection market.

The autoinjectors, which uses cyclic olefin plastic and glass primary drug containers, deliver both non-viscous and viscous drugs.

Cyclic olefin plastic will be used to create primary drug container, helping to avoid the use of glass. It will also enable to produce any shape or size due to larger volumes.

Pharmaceutical companies will use the autoinjector platform for the drug delivery systems.

The firm’s customised autoinjectors can deliver up to 3 ml of drug formulations with viscosities up to100 centipoise. It also develops devices to deliver formulations with much higher viscosities

SMC president and founder Chetan Patel said: “We are excited to have Oval Medical Technologies within the SMC family.

“SMC’s years of experience in medical device contract manufacturing paired with Oval’s innovative approach to drug delivery combination products creates a complete solution for the pharmaceutical market.”

Oval Medical Technologies CEO Barbara Lead said: “Pharmaceutical companies require reliable customized devices for their high value biologics. As part of SMC, Oval will be well placed to provide customers with devices that meet their needs and those of their patients.”

SMC offers contract manufacturing solutions of single-use devices for the pharmaceutical, medical and diagnostics industries.

Image: Oval Medical’s autoinjectors deliver both non-viscous and viscous drugs. Photo: courtesy of SMC Ltd.